Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.59 |
| ▸ | LDHA | P00338 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | DDO | Q99489 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 2/20 | 0.46 |
| ▸ | CES1 | P23141 | 2/20 | 0.46 |
| ▸ | TPMT | P51580 | 3/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8999884 | 0.84 | CES2 (0.48) | HCAR1LDHAKDM4EALDH1A1LMNA | |
| SCHEMBL109155 | 0.83 | KDM4E (0.56) | HCAR1KDM4EALDH1A1LMNAMEN1 | |
| SCHEMBL336433 | 0.83 | HCAR1 (0.73) | HCAR1KDM4EALDH1A1LMNAHCAR2 | |
| SCHEMBL157714 | 0.83 | HCAR1 (0.73) | HCAR1KDM4EALDH1A1LMNAHCAR2 | |
| SCHEMBL2820215 | 0.83 | KDM4E (0.56) | KDM4EALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL223304 | 0.83 | KDM4E (0.56) | KDM4EALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL3090976 | 0.82 | PARP1 (0.52) | HCAR1LDHAKDM4EHCAR2CES2 | |
| SCHEMBL2888306 | 0.80 | KDM4E (0.54) | HCAR1KDM4EALDH1A1LMNAMEN1 | |
| SCHEMBL1478628 | 0.80 | KDM4E (0.54) | HCAR1KDM4EALDH1A1LMNAMEN1 | |
| Hydrochloric Acid SCHEMBL8653192 | 0.80 | KDM4E (0.54) | KDM4EALDH1A1LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 240 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117800914-B | Anti-SARS-CoV-2 virus armstrong mutant inhibitor | 中国人民解放军海军军医大学 | 2026-05-19 | — | — | CN | claimed |
| CN-113174241-B | Graphene synergistic heat storage composite material and preparation method and application thereof | 山西大同大学 | 2022-04-08 | — | — | CN | claimed |
| CN-113174241-A | Graphene synergistic heat storage composite material and preparation method and application thereof | 山西大同大学 | 2021-07-27 | — | — | CN | claimed |
| CN-106831792-A | A kind of preparation method of PARP inhibitor Rucaparib intermediates | 青岛辰达生物科技有限公司 | 2017-06-13 | — | — | CN | claimed |
| CN-106748958-A | A kind of preparation method of Rucaparib intermediates | 青岛辰达生物科技有限公司 | 2017-05-31 | — | — | CN | claimed |
| EP-1973883-B1 | NOVEL COMPOUNDS AND METHODS FOR THEIR PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2012-07-11 | — | — | EP | claimed |
| US-20110021481-A1 | Novel Compounds and Methods for Their Production | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-27 | — | — | US | claimed |
| CN-101578268-A | Novel compounds and methods for their production | BIOTICA TECH LTD (GB) | 2009-11-11 | — | — | CN | claimed |
| US-20090253667-A1 | 18 ,21-Didesoxymacbecin Derivatives for the Treatment of Cancer | BIOTICA TECHNOLOGY LIMITED (GB) | 2009-10-08 | — | — | US | claimed |
| CN-101460465-A | 18,21-didesoxymacbecin derivatives for the treatment of cancer | BIOTICA TECH LTD (GB) | 2009-06-17 | — | — | CN | claimed |
| EP-1973883-A2 | NOVEL COMPOUNDS AND METHODS FOR THEIR PRODUCTION | Biotica Technology Limited (GB) | 2008-10-01 | — | — | EP | claimed |
| EP-1928837-A2 | 18,21-DIDESOXYMACBECIN DERIVATIVES FOR THE TREATMENT OF CANCER | Biotica Technology Limited (GB) | 2008-06-11 | — | — | EP | claimed |
| WO-2008056188-A2 | NOVEL COMPOUNDS AND METHODS FOR THEIR PRODUCTION | BIOTICA TECHNOLOGY LIMITED (GB) | 2008-05-15 | — | — | WO | claimed |
| WO-2007128829-A2 | 18,21-DIDESOXYMACBECIN DERIVATIVES FOR THE TREATMENT OF CANCER | BIOTICA TECHNOLOGY LIMITED (GB) | 2007-11-15 | — | — | WO | claimed |
| US-20260144743-A1 | COMPOUNDS | TMEM16A LIMITED (GB) | 2026-05-28 | — | — | US | disclosed |
| CN-117800914-B | Anti-SARS-CoV-2 virus armstrong mutant inhibitor | 中国人民解放军海军军医大学 | 2026-05-19 | — | — | CN | disclosed |
| CN-116323601-B | 2- (3-Pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl) -acetamide derivatives as transforming growth factor-beta receptor I/ALK5 inhibitors | 阿戈麦布西班牙股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-0831845-A4 | DIPHOSPHONATE DERIVATIVES OF THERAPEUTIC AGENTS | ELIZANOR BIOPHARMACEUTICALS IN (US) | 1998-12-02 | — | — | EP | disclosed |
| EP-0831845-A1 | DIPHOSPHONATE DERIVATIVES OF THERAPEUTIC AGENTS | Elizanor Biopharmaceuticals, Inc. (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996040156-A1 | DIPHOSPHONATE DERIVATIVES OF THERAPEUTIC AGENTS | ELIZANOR BIOPHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144743-A1 | COMPOUNDS | CACNA1E, TMEM109, CACNA1C | HCAR1 263/4885LDHA 2540/4885KDM4E 3794/4885 |
| US-20090253667-A1 | 18 ,21-Didesoxymacbecin Derivatives for the Treatment of Cancer | BCL3, BECN1, CD22 | HCAR1 666/4885LDHA 4179/4885KDM4E 1367/4885 |
| US-20110021481-A1 | Novel Compounds and Methods for Their Production | BCL6, BCL3, AQP4 | HCAR1 1818/4885LDHA 3729/4885KDM4E 2782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.